BACKGROUND: The generation of heterovariant immunity is a highly desirable feature of influenza vaccines. The goal of this study was to compare the heterovariant B-cell response induced by the monovalent inactivated 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) vaccine with that induced by the 2009 seasonal trivalent influenza vaccine (sTIV) containing a seasonal influenza A virus subtype H1N1 (A[H1N1]) component in young and elderly adults. METHODS: Plasmablast-derived polyclonal antibodies (PPAb) from young and elderly recipients of A(H1N1)pdm09 vaccine or sTIV were tested for binding activity to various influenza antigens. RESULTS: In A(H1N1)pdm09 recipients, the PPAb titers against homotypic A(H1N1)pdm09 vaccine were similar to those against the heterovariant seasonal A(H1N1) vaccine and were similar between young and elderly subjects. The PPAb avidity was higher among elderly individuals, compared with young individuals. In contrast, the young sTIV recipients had 10-fold lower heterovariant PPAb titers against the A(H1N1)pdm09 vaccine than against the homotypic seasonal A(H1N1) vaccine. In binding assays with recombinant head and stalk domains of hemagglutinin, PPAb from the A(H1N1)pdm09 recipients but not PPAb from the sTIV recipients bound to the conserved stalk domain. CONCLUSION: The A(H1N1)pdm09 vaccine induced production of PPAb with heterovariant reactivity, including antibodies targeting the conserved hemagglutinin stalk domain.
BACKGROUND: The generation of heterovariant immunity is a highly desirable feature of influenza vaccines. The goal of this study was to compare the heterovariant B-cell response induced by the monovalent inactivated 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) vaccine with that induced by the 2009 seasonal trivalent influenza vaccine (sTIV) containing a seasonal influenza A virus subtype H1N1 (A[H1N1]) component in young and elderly adults. METHODS: Plasmablast-derived polyclonal antibodies (PPAb) from young and elderly recipients of A(H1N1)pdm09 vaccine or sTIV were tested for binding activity to various influenza antigens. RESULTS: In A(H1N1)pdm09 recipients, the PPAb titers against homotypic A(H1N1)pdm09 vaccine were similar to those against the heterovariant seasonal A(H1N1) vaccine and were similar between young and elderly subjects. The PPAb avidity was higher among elderly individuals, compared with young individuals. In contrast, the young sTIV recipients had 10-fold lower heterovariant PPAb titers against the A(H1N1)pdm09 vaccine than against the homotypic seasonal A(H1N1) vaccine. In binding assays with recombinant head and stalk domains of hemagglutinin, PPAb from the A(H1N1)pdm09 recipients but not PPAb from the sTIV recipients bound to the conserved stalk domain. CONCLUSION: The A(H1N1)pdm09 vaccine induced production of PPAb with heterovariant reactivity, including antibodies targeting the conserved hemagglutinin stalk domain.
Authors: Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham Journal: PLoS Med Date: 2010-04-06 Impact factor: 11.069
Authors: Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245
Authors: Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson Journal: Nature Date: 2008-04-30 Impact factor: 49.962
Authors: Daniela Frasca; Ana Marie Landin; Suzanne C Lechner; John G Ryan; Robert Schwartz; Richard L Riley; Bonnie B Blomberg Journal: J Immunol Date: 2008-04-15 Impact factor: 5.422
Authors: Jianhua Sui; Jared Sheehan; William C Hwang; Laurie A Bankston; Sandra K Burchett; Chiung-Yu Huang; Robert C Liddington; John H Beigel; Wayne A Marasco Journal: Clin Infect Dis Date: 2011-04-15 Impact factor: 9.079
Authors: Mrinmoy Sanyal; Tyson H Holmes; Holden T Maecker; Randy A Albrecht; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg Journal: J Infect Dis Date: 2019-04-19 Impact factor: 5.226
Authors: Sanae Sasaki; Tyson H Holmes; Randy A Albrecht; Adolfo García-Sastre; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg Journal: J Infect Dis Date: 2014-03-27 Impact factor: 5.226
Authors: Yann-Chong Tan; Lisa K Blum; Sarah Kongpachith; Chia-Hsin Ju; Xiaoyong Cai; Tamsin M Lindstrom; Jeremy Sokolove; William H Robinson Journal: Clin Immunol Date: 2014-01-09 Impact factor: 3.969
Authors: Mark Y Sangster; Jane Baer; Felix W Santiago; Theresa Fitzgerald; Natalia A Ilyushina; Aarthi Sundararajan; Alicia D Henn; Florian Krammer; Hongmei Yang; Catherine J Luke; Martin S Zand; Peter F Wright; John J Treanor; David J Topham; Kanta Subbarao Journal: Clin Vaccine Immunol Date: 2013-04-10
Authors: Xiao-Song He; Tyson H Holmes; Mrinmoy Sanyal; Randy A Albrecht; Adolfo García-Sastre; Cornelia L Dekker; Mark M Davis; Harry B Greenberg Journal: J Infect Dis Date: 2014-10-21 Impact factor: 5.226